Document Type : Original Article


1 Department of Pathobiology, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran

2 Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran

3 PhD Candidate, Department of Microbiology, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran


Sepsis is an acute condition caused by the systemic inflammatory response syndrome to an infection. There are very few drugs that could improve the severe conditions in patients with sepsis. Hence, it is important to consider different treatment options. In this survey, we studied the effect of adenosine N1-oxide (ANO) and pioglitazone on rats with cecal ligation and perforation (CLP). They were randomly divided to four groups (n = 10) including Group A: as control group receiving normal saline, Group B: the rats with CLP as surgical control group, Group C: the rats receiving ANO, and Group D: the rats receiving pioglitazone. Interleukin (IL) -6, IL-1β, tumor necrosis factor alpha (TNF-α), nitric-oxide (NO) in serum blood and superoxide dismutase (SOD), catalase (CAT) malondialdehyde, (MDA) and myeloperoxidase (MPO) in liver and spleen homogenates were measured. The amount of antioxidant enzymes in the spleen and liver, and finally cell viability and rats’ survival were investigated. The measurement of blood serum nitric-oxide and survival of all groups of rats were also performed. The results indicated that both drugs could cause a decrease in IL-1β, IL-6, TNF-α and NO in rat blood serum and MDA and MPO in the liver and spleen homogenates, however, a significant increase in SOD and CAT in the liver and spleen homogenates in rats that received ANO and pioglitazone was observed compared to rats with CLP group. Cell viability and rats’ survival were significantly improved in rats that received ANO and pioglitazone compared to rats with CLP group. Adenosine N1-oxide showed stronger and more effective effects.


Main Subjects

  1. Chaudhry H, Zhou J, Zhong Y, et al. Role of cytokines as a double-edged sword in sepsis. In Vivo 2013; 27(6): 669-684.
  2. Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol 2017; 39(5): 517-528.
  3. Janeway CA Jr, Travers P, Walport M, et al. Induced innate responses to infection. New York, USA: CRC Press 2001; 77-137.
  4. Salvemini D, Cuzzocrea S. Oxidative stress in septic shock and disseminated intravascular coagulation. Free Radic Biol Med 2002; 33(9): 1173-1185.
  5. Zimmerman JJ. Defining the role of oxyradicals in the pathogenesis of sepsis. Crit Care Med 1995; 23(4): 616-617.
  6. Víctor VM, Espulgues JV, Hernández-Mijares A, et al. Oxidative stress and mitochondrial dysfunction in sepsis: a potential therapy with mitochondria-targeted antioxidants. Infect Disord Drug Targets 2009; 9(4): 376-389.
  7. Ritter C, Andrades M, Frota Júnior ML, et al. Oxidative parameters and mortality in sepsis induced by cecal ligation and perforation. Intensive Care Med 2003; 29(10): 1782-1789.
  8. Dalle-Donne I, Rossi R, Colombo R, et al. Biomarkers of oxidative damage in human disease. Clin Chem 2006; 52(4): 601-623.
  9. Lorente L, Martín MM, Abreu-González P, et al. Prognostic value of malondialdehyde serum levels in severe sepsis: a multicenter study. PLoS One 2013; 8(1): e53741. doi: 10.1371/journal.pone.0053741.
  10. Winterbourn CC, Kettle AJ, Hampton MB. Reactive oxygen species and neutrophil function. Annu Rev Biochem 2016; 85: 765-792.
  11. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320(6):365-376.
  12. Gaweł S, Wardas M, Niedworok E, et al. Malondialdehyde (MDA) as a lipid peroxidation marker [Polish]. Wiad Lek 2004; 57(9-10): 453-455.
  13. Kaplan J, Nowell M, Chima R, et al. Pioglitazone reduces inflammation through inhibition of NF-κB in poly-microbial sepsis. Innate Immun 2014; 20(5): 519-528.
  14. Ohashi E, Kohno K, Arai N, et al. Adenosine N1-oxide exerts anti-inflammatory effects through the PI3K/Akt/GSK-3β signaling pathway and promotes osteogenic and adipocyte differentiation. Biol Pharm Bull 2019; 42(6): 968-976.
  15. Hubbard WJ, Choudhry M, Schwacha MG, et al. Cecal ligation and puncture. Shock 2005; 24(Suppl 1): 52-57.
  16. Kohno K, Ohashi E, Sano O, et al. Anti-inflammatory effects of adenosine N1-oxide. J Inflamm (Lond) 2015;12(1): 2. doi: 10.1186/s12950-014-0045-0.
  17. Griess P. Remarks on the treatise of HH. Weselsky and Benedikt "On some azo compounds" [German]. Angew Chem Int Ed 1879; 12(1), 426-428.
  18. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95(2): 351-358.
  19. Nishikimi M, Appaji N, Yagi K. The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen. Biochem Biophys Res Commun 1972; 46(2): 849-854.
  20. Aebi H. Catalase in vitro. Methods Enzymol 1984; 105: 121-126.
  21. Cannon JG, Tompkins RG, Gelfand JA, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161(1): 79-84.
  22. Frimpong A, Owusu EDA, Amponsah JA, et al. Cytokines as potential biomarkers for differential diagnosis of sepsis and other non-septic disease conditions. Front Cell Infect Microbiol 2022; 12: 901433. doi: 10.3389/fcimb.2022.901433.
  23. Cohen J. The immunopathogenesis of sepsis. Nature 2002; 420(6917): 885-891.
  24. Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets - - an updated view. Mediators Inflamm 2013; 2013: 165974. doi: 10.1155/2013/165974.
  25. Parmely MJ, Zhou WW, Edwards CK 3rd, et al. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J Immunol 1993; 151(1): 389-396.
  26. Zingarelli B, Cook JA. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 2005; 23(5): 393-399.
  27. Shafaroodi H, Hassanipour M, Mousavi Z, et al. The effects of sub-chronic treatment with pioglitazone on the septic mice mortality in the model of cecal ligation and puncture: involvement of nitric oxide pathway. Acta Med Iran 2015; 53(10): 608-616.
  28. Gao BT, Lee RP, Jiang Y, et al. Pioglitazone alters monocyte populations and stimulates recent thymic emigrants in the BBDZR/Wor type 2 diabetes rat model. Diabetol Metab Syndr 2015; 7: 72. doi: 10.1186/s13098-015-0068-6.
  29. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391(6662): 82-86.
  30. Feihl F, Waeber B, Liaudet L. Is nitric oxide overproduction the target of choice for the management of septic shock? Pharmacol Ther 2001; 91(3): 179-213.
  31. Sakaguchi S, Furusawa S. Oxidative stress and septic shock: metabolic aspects of oxygen-derived free radicals generated in the liver during endotoxemia. FEMS Immunol Med Microbiol 2006; 47(2): 167-177.
  32. Kumar S, Gupta E, Kaushik S, et al. Evaluation of oxidative stress and antioxidant status: correlation with the severity of sepsis. Scand J Immunol 2018; 87(4): e12653. doi: 10.1111/sji.12653.
  33. Grommes J, Vijayan S, Drechsler M, et al. Simvastatin reduces endotoxin-induced acute lung injury by decreasing neutrophil recruitment and radical formation. PLoS One 2012; 7(6): e38917. doi: 10.1371/journal.pone.0038917.
  34. Gao M, Jiang Y, Xiao X, et al. Protective effect of pioglitazone on sepsis-induced intestinal injury in a rodent model. J Surg Res 2015; 195(2): 550-558.
  35. Haraguchi G, Kosuge H, Maejima Y, et al. Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis. Intensive Care Med 2008; 34(7): 1304-1312.